Italia markets closed

Dow Jones
40.030,83
+27,24(+0,07%)
Nasdaq
16.782,94
+96,98(+0,58%)
Nikkei 225
39.069,68
+282,30(+0,73%)
EUR/USD
1,0864
-0,0008(-0,08%)
Bitcoin EUR
62.019,26
+498,31(+0,81%)
CMC Crypto 200
1.371,62
+17,20(+1,27%)

NVCR Jun 2024 30.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

0,5500

+0,4000

(+266,67%)

In data: 11:30AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in